|
¼¼°èÀÇ Àΰ£ ÀçÁ¶ÇÕ DNA ½ÃÀå
Human Recombinant DNA: Global Markets
|
¸®¼Ä¡»ç |
BCC Research
|
¹ßÇàÀÏ |
2022³â 07¿ù | »óǰÄÚµå |
1105254 |
ÆäÀÌÁö Á¤º¸ |
¿µ¹® 84 Pages
| ¹è¼Û¾È³» |
|
°¡°Ý |
|
¼¼°èÀÇ Àΰ£ ÀçÁ¶ÇÕ DNA ½ÃÀå
Human Recombinant DNA: Global Markets
|
¹ßÇàÀÏ : 2022³â 07¿ù | ÆäÀÌÁö Á¤º¸ : ¿µ¹® 84 Pages |
|
|
¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹®¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù. ¼¼°èÀÇ Àΰ£ ÀçÁ¶ÇÕ DNA ½ÃÀå ±Ô¸ð´Â 2022³â±îÁö 3,487¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
½ÃÀåÀº 2022-2027³â ¿¹Ãø±â°£ Áß 7.3%ÀÇ CAGR·Î È®´ëµÇ°í, 2027³â¿¡´Â 4,969¾ï ´Þ·¯¸¦ ³Ñ¾î¼³ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
¼¼°èÀÇ Àΰ£ ÀçÁ¶ÇÕ DNA(Human Recombinant DNA) ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä¿Í ÇÔ²² Á¦Ç° Á¾·ùº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° µ¿Çâ, COVID-19ÀÇ ¿µÇâ ¹× ½ÃÀå¿¡ Âü¿©ÇÏ´Â ±â¾÷ °³¿ä µîÀ» Á¦°øÇÕ´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¼·Ð
Á¦2Àå Á¤¸®¿Í ÇÏÀ̶óÀÌÆ®
Á¦3Àå °³¿ä
Á¦4Àå COVID-19 ÆÒµ¥¹ÍÀÇ ¿µÇâ
Á¦5Àå ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
- ½ÃÀå ±âȸ
Á¦6Àå ½ÃÀå ³»¿ª, Á¦Ç° Á¾·ùº°
- Àΰ£ ´Ü¹éÁú ġȯ
- Àΰ£ ÁúȯÀ» À§ÇÑ Ä¡·áÁ¦
- ¹é½Å
- ¹é½Å Á¾·ù
Á¦7Àå ½ÃÀå ³»¿ª, ÃÖÁ¾»ç¿ëÀÚº°
- ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ¾÷°è, Á¦¾à »ê¾÷
- Çмú¿¬±¸±â°ü
Á¦8Àå ½ÃÀå ³»¿ª, Áö¿ªº°
- Áö¿ªº° ¼¼°è ½ÃÀå
- ºÏ¹Ì
- À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ±âŸ Áö¿ª
Á¦9Àå °æÀï »óȲ
Á¦10Àå ±â¾÷ °³¿ä
- ABBVIE INC.
- ALEXION PHARMACEUTICALS
- AMGEN INC.
- ELI LILLY
- MERCK & CO. INC.
- SANOFI S.A.
- TAKEDA PHARMACEUTICAL CO LTD.
KSM 22.08.05
List of Tables
- Summary Table : Global Market for Human Recombinant DNA, by Region, Through 2027
- Table 1 : Estimated World Population and Annual Growth, by Selected Age Group, Through 2030
- Table 2 : Cancer Statistics Across Major Asian Countries, by Cancer Site/Type, 2020
- Table 3 : Global Human Recombinant DNA Market, by Product Type, Through 2027
- Table 4 : Global Market for Human Protein Replacements, by Region, Through 2027
- Table 5 : Global Market for Therapeutic Agents for Human Diseases, by Region, Through 2027
- Table 6 : Vaccine Types
- Table 7 : Global Market for Vaccines, by Region, Through 2027
- Table 8 : Global Market for Human Recombinant DNA, by End User, Through 2027
- Table 9 : Global Market for Human Recombinant DNA in the Biotechnology and Pharmaceutical Industry, by Region, Through 2027
- Table 10 : Global Market for Human Recombinant DNA in Research Laboratories and Academic Institutes, by Region, Through 2027
- Table 11 : Global Market for Human Recombinant DNA, by Region, Through 2027
- Table 12 : North American Market for Human Recombinant DNA, by Product Type Through 2027
- Table 13 : North American Market for Human Recombinant DNA, by End User, Through 2027
- Table 14 : North American Market for Human Recombinant DNA, by Country, Through 2027
- Table 15 : European Market for Human Recombinant DNA, by Product Type, Through 2027
- Table 16 : European Human Recombinant DNA Market, by End User, Through 2027
- Table 17 : European Market for Human Recombinant DNA, by Country, Through 2027
- Table 18 : Asia-Pacific Market for Human Recombinant DNA, by Product Type, Through 2027
- Table 19 : Asia-Pacific Human Recombinant DNA Market, by End User, Through 2027
- Table 20 : Asia-Pacific Market for Human Recombinant DNA, by Country, Through 2027
- Table 21 : Japan: Total Number of New Cancer Cases in Both Genders, 2020
- Table 22 : RoW Market for Human Recombinant DNA, by Product Type, Through 2027
- Table 23 : RoW Market for Human Recombinant DNA, by End User, Through 2027
- Table 24 : Leading Market Players in the Human Recombinant DNA Market Ecosystem
- Table 25 : AbbVie Inc.: Business Segments
- Table 26 : AbbVie Inc.: Financial Performance, Through 2020
- Table 27 : Amgen: Financial Performance, Through 2020
- Table 28 : Eli Lilly: Business Segments
- Table 29 : Eli Lilly: Financial Performance, 2018-2020
- Table 30 : Sanofi: Business Segments
- Table 31 : Sanofi: Financial Performance, 2018-2020
List of Figures
- Summary Figure A : Global Market for Human Recombinant DNA, by Region, 2020-2027
- Summary Figure B : Global Market Shares of Human Recombinant DNA, by Region, 2021
- Figure 1 : Global Market Shares of Human Recombinant DNA, by Product Type, 2021
- Figure 2 : Global Market for Human Recombinant DNA, by Product Type, 2020-2027
- Figure 3 : Global Market for Human Protein Replacements, 2020-2027
- Figure 4 : Global Market for Therapeutic Agents for Human Diseases, 2020-2027
- Figure 5 : Evolution of Vaccine Technologies
- Figure 6 : Global Market for Vaccines, 2020-2027
- Figure 7 : Global Market Shares of Human Recombinant DNA, by End User, 2021
- Figure 8 : Global Market for Human Recombinant DNA, by End User, 2020-2027
- Figure 9 : Global Market for Human Recombinant DNA in the Biotechnology and Pharmaceutical Industry, 2020-2027
- Figure 10 : Global Market for Human Recombinant DNA in Research Laboratories and Academic Institutes, 2020-2027
- Figure 11 : Global Market Shares of Human Recombinant DNA, by Region, 2021
- Figure 12 : North American Market Shares of Human Recombinant DNA, by Product Type, 2021
- Figure 13 : North American Market Shares of Human Recombinant DNA, by End User, 2021
- Figure 14 : North American Market Shares of Human Recombinant DNA, by Country, 2021
- Figure 15 : U.S. Market for Human Recombinant DNA, 2020-2027
- Figure 16 : Canadian Market for Human Recombinant DNA, 2020-2027
- Figure 17 : European Market Shares of Human Recombinant DNA, by Product Type, 2021
- Figure 18 : European Human Recombinant DNA Market, Market Shares, by End User, 2021
- Figure 19 : European Market Shares of Human Recombinant DNA, by Country, 2021
- Figure 20 : Geriatric Population in Germany, 2000-2030
- Figure 21 : German Market for Human Recombinant DNA, 2020-2027
- Figure 22 : U.K. Market for Human Recombinant DNA, 2020-2027
- Figure 23 : French Market for Human Recombinant DNA, 2020-2027
- Figure 24 : Italian Market for Human Recombinant DNA, 2020-2027
- Figure 25 : Spanish Market for Human Recombinant DNA, 2020-2027
- Figure 26 : Rest of Europe Market for Human Recombinant DNA, 2020-2027
- Figure 27 : Asia-Pacific Market Shares of Human Recombinant DNA, by Product Type, 2021
- Figure 28 : Asia-Pacific Human Recombinant DNA Market, Market Shares, by End User, 2021
- Figure 29 : Asia-Pacific Market Shares of Human Recombinant DNA, by Country, 2021
- Figure 30 : New Cancer Cases in China, 2020
- Figure 31 : Distribution of New Cancer Cases in China, 2020
- Figure 32 : Chinese Market for Human Recombinant DNA, 2020-2027
- Figure 33 : Japanese Market for Human Recombinant DNA, 2020-2027
- Figure 34 : Indian Market for Human Recombinant DNA, 2020-2027
- Figure 35 : Rest of Asia-Pacific Market for Human Recombinant DNA, 2020-2027
- Figure 36 : New Cancer Cases in Africa, 2020
- Figure 37 : RoW Market Shares of Human Recombinant DNA, by Product Type, 2021
- Figure 38 : RoW Market Shares of Human Recombinant DNA, by End User, 2021
- Figure 39 : AbbVie Inc.: Net Revenue, by Business Segment, 2020
- Figure 40 : AbbVie Inc.: Net Revenue, by Region, 2020
- Figure 41 : Amgen: Total Sales, by Product, 2020
- Figure 42 : Amgen: Total Revenue, by Region, 2020
- Figure 43 : Eli Lilly: Total Sales, by Product Segment, 2020
- Figure 44 : Eli Lilly: Total Revenue, by Region, 2020
- Figure 45 : Sanofi: Net Sales, by Business Segment, 2020
- Figure 46 : Sanofi: Net Sales, by Region, 2020
Highlights:
The global human recombinant DNA market should reach $348.7 billion by 2022 and more than $496.9 billion by 2027, with a compound annual growth rate (CAGR) of 7.3% during the forecast period of 2022-2027.
North American human recombinant DNA market should reach $150.8 billion by 2022 and more than $191.7 billion by 2027, with a CAGR of 4.9% during the forecast period of 2022-2027.
Asia-Pacific human recombinant DNA market should reach $86 billion by 2022 and more than $136.2 billion by 2027, with a CAGR of 9.6% during the forecast period of 2022-2027.
Report Scope:
This report highlights the current and future market potential for human recombinant DNA and provides a detailed analysis of the competitive environment, regulatory scenario, drivers, restraints, opportunities, trends and key players in the market. The report also provides market projections from 2022 through 2027. An in-depth discussion of strategic alliances, industry structures, competitive dynamics, and market forces are also provided.
Report Includes:
- 24 data tables and 8 additional tables
- An overview of the global market for human recombinant DNA
- Estimation of the market size and analyses of global market trends, with data from 2020, 2021 with projections of compound annual growth rates (CAGRs) through 2026
- Highlights of the market potential for human recombinant DNA, based on product, application, and region
- Coverage of history and future of human recombinant DNA, and latest technological advancements of the industry
- Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast
- Coverage of regulatory landscape, product recalls, pipeline products, and discussion on future perspective, strategies, and developments of the industry
- Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies and a relevant patent analysis
- Company profiles of major players within the industry AbbVie Inc., Amgen Inc., Eli Lilly, Sanofi
Table of Contents
Chapter 1 Introduction
- Introduction
- Study Goals and Objectives
- Reasons for Doing the Study
- Intended Audience
- Scope and Format
- Methodology
- Market Estimates
- Information Sources
- Geographical Breakdown
- Analyst's Credentials
- BCC Custom Research
- Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Overview
- Homologous Recombination (HR)
- Targets for Cancer Therapy
Chapter 4 Impact of COVID-19 Pandemic
Chapter 5 Market Dynamics
- Market Drivers
- Increasing Incidences of Chronic Diseases
- Growing Aging Population
- Advancements in Manufacturing Technologies
- Market Restraints
- Price Controls
- Entry of Biosimilars
- Opportunities
- Untapped Potential in Emerging Markets
Chapter 6 Market Breakdown by Product Type
- Human Protein Replacements
- Market Size and Forecast
- Therapeutic Agents for Human Diseases
- Market Size and Forecast
- Vaccines
- Types of Vaccines
- Market Size and Forecast
Chapter 7 Market Breakdown by End User
- Biotechnology and Pharmaceutical Industry
- Market Size and Forecast
- Research Laboratories and Academic Institutes
- Market Size and Forecast
Chapter 8 Market Breakdown by Region
- Global Market by Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
Chapter 9 Competitive Landscape
Chapter 10 Company Profiles
- ABBVIE INC.
- ALEXION PHARMACEUTICALS
- AMGEN INC.
- ELI LILLY
- MERCK & CO. INC.
- SANOFI S.A.
- TAKEDA PHARMACEUTICAL CO LTD.
|

|
ÀçÁ¶ÇÕ DNA ±â¼ú ½ÃÀå : Á¦Ç° À¯Çüº°, ¿ëµµº°, Áö¿ªº° - ±Ô¸ð, Á¡À¯À², Àü¸Á, ±âȸ ºÐ¼®(2022-2030³â)
¼¼°èÀÇ ÀçÁ¶ÇÕ DNA ±â¼ú ½ÃÀå : ¾÷°è µ¿Çâ, Á¡À¯À², ±Ô¸ð, ¼ºÀå, ±âȸ, ¿¹Ãø(2022-2027³â)
¼¼°èÀÇ ÀçÁ¶ÇÕ DNA(rDNA) ±â¼ú ½ÃÀå : ¼ºÀå, µ¿Çâ, ¿¹Ãø(2019-2024³â)
¼¼°èÀÇ ÀçÁ¶ÇÕ DNA ±â¼ú ½ÃÀå
¼¼°èÀÇ ÀçÁ¶ÇÕ DNA ±â¼ú ½ÃÀå(2020-2027³â)
|